The present invention relates to a genetically modified pig as a model for studying atherosclerosis. The modified pig model displays one or more phenotypes associated with atherosclerosis. Disclosed is also a modified pig comprising a mutation in the endogenous ApoE gene or part thereof, LDL gene or part thereof, LDL receptor gene, or transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig and methods for evaluating the effect of a therapeutical treatment of atherosclerosis methods for screening the efficacy of a pharmaceutical composition and a method for treatment of a human being suffering from atherosclerosis are disclosed.
